heart attack

Showing 15 posts of 17 posts found.


NHS to pioneer Novartis injection that reduces cholesterol

January 14, 2020
Manufacturing and Production NHS, NHS England, bad cholesterol, cholesterol, heart attack

The NHS in England is pioneering a new twice-a-year injection, inclisiran, which reduces bad cholesterol.It has reached a deal with …


“Triple pill” blood pressure combo proves more effective, safe than standard care

August 16, 2018
Research and Development blood pressure, heart attack, heart disease, pharma, triple pill

A “triple pill” combining three established and effective drugs at low dosage levels could prove much more effective in treating …


Researchers design new class of drugs to counter cardiovascular disease

August 14, 2018
Manufacturing and Production TMAO, cardiovascular, gut microbe, heart attack, research

Cleveland Clinic researchers have designed a potential new class of drugs that may reduce the risk of cardiovascular disease by …


Abbvie pays out over $3m after its testosterone replacement drug leads to heart attack

March 27, 2018
Manufacturing and Production, Sales and Marketing AbbVie, Endo, GSK, androgel, heart attack, pharma

Abbvie has been ordered to pay over $3 million in damages to a man who asserts that the uise of …


AstraZeneca’s Brilinta proves safety in heart attack patients at Phase 3

March 12, 2018
Research and Development, Sales and Marketing AstraZeneca, Brilinta, heart attack

AstraZeneca has revealed new Phase 3 data on its direct-acting P2Y12 receptor antagonist Brilinta (ticagrelor) at the American College of …


Novartis targets specific patient population with strong Ilaris Phase 3 data

November 14, 2017
Manufacturing and Production, Research and Development Ilaris, Novartis, cardiovascular, heart attack, heart disease, pharma

Novartis has presented new Phase 3 data on its cardiovascular drug Ilaris (canakinumab) which demonstrate particular efficacy in a specific …


Improved heart attack test could save millions for NHS

September 27, 2017
Research and Development biotech, drugs, heart attack, pharma, pharmaceutical

A new research, funded by the British Heart Foundation, has led to the creation of a new heart attack test …


AstraZeneca’s Brilinta protects against adverse cardiovascular events for up to 5 years, new data reveals

September 7, 2017
Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, pharma, pharmaceutical, ticagrelor, trial

AstraZeneca has revealed new data supporting the long-term use and efficacy of its cardiovascular drug Brilinta (ticagrelor), showing that the …


MSD scores trial success in reducing cardiovascular risk

August 29, 2017
Manufacturing and Production, Research and Development MSD, heart attack, heart disease, life sciences, pharma, pharmaceutical

New data on MSD’s anacetrapib has revealed that the drug was able to reduce risk of the risk of major …


Extended use of AstraZeneca’s Brilinta reduces cardiovascular death risk

August 24, 2017
Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, life sciences, pharma, pharmaceutical

New data for AstraZeneca’s blood thinner Brilinta (ticagrelor) has shown that extended use of the drug can cut the risk …


Beta blockers offer little to no benefit for heart attack patients, study suggests

May 30, 2017
Manufacturing and Production, Research and Development beta-blockers, heart attack

New research from the University of Leeds has called into question the prevalent practice of prescribing beta blockers for heart …


TiGenix announces success of novel heart attack stem cell trial

March 13, 2017
Research and Development, Sales and Marketing Stem cells, TiGenix, heart attack

Belgium’s TiGenix has announced the success of its top-line Phase 2/3 study investigating the effects of donor-derived expanded cardiac stem …


AstraZeneca’s post-heart attack drug gets NICE recommendation

November 4, 2016
Medical Communications, Sales and Marketing AstraZeneca, Brillique, NICE, heart attack

AstraZeneca’s Brillique (ticagrelor) has received final recommendation from the National Institute of Health and Care Excellence (NICE) as a prevention …


Lilly and Boehringer Ingelheim to evaluate diabetes drug for treatment of heart failure

April 20, 2016
Research and Development Boehringer Ingelheim, Eli Lilly, cardiovascular death, diabetes, heart attack, jardiance, lilly

Eli Lilly (NYSE: LLY) and Boehringer Ingelheim have announced plans to conduct two outcome trials evaluating diabetes medicine Jardiance (empagliflozin) …

Latest content